Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities.

Dian, Yating; Meng, Yu; Sun, Yuming; Deng, Guangtong; Zeng, Furong

Dian, Yating; Meng, Yu; Sun, Yuming; Deng, Guangtong; Zeng, Furong.

Afiliação

Dian Y; Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China; Furong Laboratory, Changsha, Hunan 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis
Meng Y; Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China; Furong Laboratory, Changsha, Hunan 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis
Sun Y; Department of Plastic and Cosmetic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Deng G; Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China; Furong Laboratory, Changsha, Hunan 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis
Zeng F; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. Electronic address: zengflorachn@hotmail.com.

J Infect ; 87(2): e24-e27, 2023 08.

Article em En | MEDLINE | ID: mdl-37207823

Assuntos

Antivirais; Tratamento Farmacológico da COVID-19; COVID-19; Humanos; Azidas; População do Leste Asiático; Antivirais/uso terapêutico; Comorbidade

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / COVID-19 / Tratamento Farmacológico da COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google